| scholarly article | Q13442814 |
| P356 | DOI | 10.1056/NEJMCIBR060065 |
| P8608 | Fatcat ID | release_sqx5bl6ycvamfkz6nkgwqgvuhy |
| P3181 | OpenCitations bibliographic resource ID | 1857382 |
| P698 | PubMed publication ID | 16540623 |
| P5875 | ResearchGate publication ID | 7237331 |
| P2093 | author name string | Michael P Czech | |
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | microRNA | Q310899 |
| P304 | page(s) | 1194-5 | |
| P577 | publication date | 2006-03-16 | |
| P1433 | published in | The New England Journal of Medicine | Q582728 |
| P1476 | title | MicroRNAs as therapeutic targets | |
| P478 | volume | 354 |
| Q36870444 | Antiviral Stratagems Against HIV-1 Using RNA Interference (RNAi) Technology |
| Q21135312 | Bioinformatic and genetic association analysis of microRNA target sites in one-carbon metabolism genes |
| Q38324942 | Cellular uptakes, biostabilities and anti-miR-210 activities of chiral arginine-PNAs in leukaemic K562 cells |
| Q98177854 | Development of MicroRNAs as Potential Therapeutics against Cancer |
| Q39037574 | Differential expression of miRNAs by macrophages infected with virulent and avirulent Mycobacterium tuberculosis |
| Q38152825 | Epigenetic dysregulation in systemic lupus erythematosus |
| Q42039163 | Grand challenges in pharmacotherapy of inflammation for the first decades of the 21st century |
| Q33842759 | High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2. |
| Q36082773 | Immunopathologic processes in sympathetic ophthalmia as signified by microRNA profiling |
| Q38323747 | Locked nucleic acid-based in situ hybridisation reveals miR-7a as a hypothalamus-enriched microRNA with a distinct expression pattern |
| Q34993023 | Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties |
| Q37193000 | Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides |
| Q57947476 | MiR-125b, a MicroRNA Downregulated in Psoriasis, Modulates Keratinocyte Proliferation by Targeting FGFR2 |
| Q35757463 | MiR-378b Promotes Differentiation of Keratinocytes through NKX3.1. |
| Q55432318 | MicroRNA Signature of Traumatic Brain Injury: From the Biomarker Discovery to the Point-of-Care. |
| Q51553464 | MicroRNA array analysis of microRNAs related to systemic scleroderma |
| Q27488310 | MicroRNA signatures in liver diseases |
| Q26747644 | MicroRNA therapeutics: Discovering novel targets and developing specific therapy |
| Q34336812 | MicroRNA-203 functions as a tumor suppressor in basal cell carcinoma |
| Q28297593 | MicroRNA-7, a homeobox D10 target, inhibits p21-activated kinase 1 and regulates its functions |
| Q64041638 | MicroRNAs and Long Non-coding RNAs in Genetic Diseases |
| Q36617820 | MicroRNAs and chromosomal abnormalities in cancer cells |
| Q38064320 | MicroRNAs as active players in the pathogenesis of multiple sclerosis |
| Q37255242 | MicroRNAs--micro in size but macro in function |
| Q21144444 | MicroRNAs: novel regulators involved in the pathogenesis of psoriasis? |
| Q36175435 | Microvesicles/exosomes as potential novel biomarkers of metabolic diseases |
| Q46035392 | Nucleoterpenes of thymidine and 2'-deoxyinosine: synthons for a biomimetic lipophilization of oligonucleotides. |
| Q34174676 | Pathophysiology of translational regulation by microRNAs in multiple sclerosis |
| Q38176989 | Peptide nucleic acids: a review on recent patents and technology transfer |
| Q58696748 | Predictive modeling of miRNA-mediated predisposition to alcohol-related phenotypes in mouse |
| Q92667875 | RNA-based diagnostic and therapeutic strategies for cardiovascular disease |
| Q97537622 | Silencing miR-370-3p rescues funny current and sinus node function in heart failure |
| Q33765140 | Small non-coding RNA signature in multiple sclerosis patients after treatment with interferon-β. |
| Q37628264 | Targeting MicroRNAs in Cancer Gene Therapy |
| Q36992190 | Targeting oncomiRNAs and mimicking tumor suppressor miRNAs: Νew trends in the development of miRNA therapeutic strategies in oncology (Review). |
| Q44118355 | Temporal expression profiles indicate a primary function for microRNA during the peak of DNA replication after rat partial hepatectomy |
| Q36021666 | The Role of miR-212 and iNOS in Alcohol-Induced Intestinal Barrier Dysfunction and Steatohepatitis |
| Q30391726 | The effect of exposure to a high-fat diet on microRNA expression in the liver of blunt snout bream (Megalobrama amblycephala) |
| Q39436568 | The effect of miR-7 on behavior and global protein expression in glioma cell lines |
| Q37820094 | The emerging role of microRNAs in multiple sclerosis |
| Q38254456 | The role of miRNAs in alcohol-induced endotoxemia, dysfunction of mucosal immunity, and gut leakiness |
| Q34080104 | Towards computational prediction of microRNA function and activity. |
| Q34979073 | Two-tiered approach identifies a network of cancer and liver disease-related genes regulated by miR-122. |
| Q42026232 | VHL-regulated MiR-204 suppresses tumor growth through inhibition of LC3B-mediated autophagy in renal clear cell carcinoma |
| Q42692995 | miR-125b Regulation of Androgen Receptor Signaling Via Modulation of the Receptor Complex Co-Repressor NCOR2. |
| Q36525161 | miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1 |
| Q37962609 | miRNA therapeutics: delivery and biological activity of peptide nucleic acids targeting miRNAs |
| Q38092617 | miRNA-Based Therapeutic Strategies |
| Q36918118 | miRNAs: from neurogeneration to neurodegeneration |
| Q93111114 | miR‑488 negatively regulates osteogenic differentiation of bone marrow mesenchymal stem cells induced by psoralen by targeting Runx2 |
| Q93055648 | siRNA- and miRNA-based therapeutics for liver fibrosis |
Search more.